摩根士丹利此前研报指，下调微创医疗2027-2030年的每股盈测5-9%，以反映在持续的定价压力下，对2027-30年的增长和利润率假设较为保守，并相应地将SOTP估值中各业务部门的折让率由10-11%调高至11-13.5%。因此，大摩下调微创医疗目标价14%，由7.4港元降至6.4港元。维持“与大市同步”评级。Microport shares surged in the morning session, as of the publication deadline, Siasun Robot&Automation-B (02252) rose by 7.77% to HK$9.85, while Microport (00853) rose by 6.41% to HK$6.81.
According to the Securities Times app, Microport shares surged in the morning session, as of the publication deadline, Siasun Robot&Automation-B (02252) rose by 7.77% to HK$9.85, while Microport (00853) rose by 6.41% to HK$6.81, and Microport Neuro Science (02172) rose by 3.7% to HK$10.08.
On the news front, market reports suggest that CKH Holdings is considering selling its stake in Microport. Sources familiar with the matter said that after receiving preliminary interest from potential investors, this Japanese pharmaceutical company is working with an advisor to evaluate its minority stake. As of June 30, 2024, CKH Holdings is the largest shareholder of Microport, holding 20.87% of its shares.
Morgan Stanley's previous research report indicated a downward revision of 5-9% in earnings per share forecasts for Microport for 2027-2030, to reflect conservative assumptions for growth and profit margins during 2027-2030 under sustained pricing pressures. Consequently, Morgan Stanley lowered the target price for Microport by 14%, from HK$7.4 to HK$6.4. The 'Equal-weight' rating is maintained in line with the market.
